Transaction DateRecipientSharesTypePriceValue
14th January 2021Trevor Hallam19,405Exercise of derivative$4.36$84,605.80
28th December 2020Trevor Hallam2,393Exercise of derivative$4.36$10,433.48
28th December 2020Trevor Hallam2,393Open or private sale$22.37$53,530.21
10th December 2020John Gordon Freund118,735Other acquisition or disposition$0.00
10th December 2020John Gordon Freund56,327Other acquisition or disposition$0.00
3rd December 2020John Gordon Freund47,886Open or private sale$23.39$1,120,197.20
2nd December 2020John Gordon Freund100,000Open or private sale$23.28$2,328,480.00
27th November 2020Trevor Hallam2,393Exercise of derivative$4.36$10,433.48
27th November 2020Trevor Hallam2,393Open or private sale$17.01$40,713.07
5th November 2020Trevor Hallam16,751Exercise of derivative$4.36$73,034.36
Sutro Biopharma
Sutro Biopharma logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 4/10.


Sutro Biopharma Inc. engages in the drug discovery, development and manufacturing of pharmaceutical products. Its products technologies include XpressCF, anti-body drug conjugates, bispecifics & engineered antibodies and cGMP facility.


Ticker: STRO
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1382101
Employees: 168
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $65 M (0%)
Marketable Securities, Current: $136 M (20%)
Assets, Current: $258 M (101%)
Property, Plant and Equipment, Net: $11 M (16%)
Other Assets, Noncurrent: $2 M (-16%)
Assets: $278 M (77%)
Accounts Payable, Current: $5 M (-12%)
Accrued Liabilities, Current: $5 M (-24%)
Liabilities, Current: $35 M (7%)
Long-term Debt, Excluding Current Maturities: $24 M (173%)
Other Liabilities, Noncurrent: $148 Th (10%)
Liabilities: $71 M (20%)
Common Stock, Value, Issued: $36 Th (56%)
Common Stock, Shares, Issued: $36 M (55%)
Additional Paid in Capital, Common Stock: $392 M (33%)
Retained Earnings (Accumulated Deficit): $185 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $398 Th (141%)
Stockholders' Equity (Parent): $207 M (0%)
Liabilities and Equity: $278 M (77%)
Revenue: $9 M (-43%)
Research and Development: $17 M (-50%)
General and Administrative Expenses: $9 M (-50%)
Operating Income/Loss: $16 M (-53%)
EPS (basic): $1 (0%)
EPS (diluted): $0.94 (0%)